We are live on ! Find out more
TRCT

Tower Research Capital (TRC) Portfolio holdings

AUM $4.08B
1-Year Est. Return 58.77%
This Fund
S&P 500
This Quarter Est. Return
+7.58%
1 Year Est. Return
+58.77%
3 Year Est. Return
+143.94%
5 Year Est. Return
+167.17%
10 Year Est. Return
+536.06%
AUM
$2.41B
AUM Growth
-$3.75B
Cap. Flow
-$4.09B
Cap. Flow %
-169.35%
Top 10 Hldgs %
31.78%
Holding
6,989
New
537
Increased
1,703
Reduced
3,620
Closed
686

Sector Composition

Rank Sector Weight
1 Technology 21.73%
2 Healthcare 7.71%
3 Consumer Discretionary 6.84%
4 Financials 6.55%
5 Industrials 4.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MAPS
3176
DELISTED
WM TECHNOLOGY INC A
MAPS
$19K ﹤0.01%
18,490
-28,499
-61% -$41.2K
MGRC icon
3177
McGrath RentCorp
MGRC
$2.97B
$19K ﹤0.01%
195
-4,297
-96% -$402K
BINI
3178
DELISTED
Bollinger Innovations
BINI
0
NEWP
3179
New Pacific Metals
NEWP
$1.27B
$19K ﹤0.01%
8,560
-40,514
-83% -$91.3K
NUVB icon
3180
Nuvation Bio
NUVB
$2.16B
$19K ﹤0.01%
9,955
+1,199
+14% +$2.43K
OTTR icon
3181
Otter Tail
OTTR
$3.89B
$19K ﹤0.01%
320
-4,159
-93% -$249K
PRG icon
3182
PROG Holdings
PRG
$1.71B
$19K ﹤0.01%
1,097
-2,739
-71% -$46.8K
PTGX icon
3183
Protagonist Therapeutics
PTGX
$9.99B
$19K ﹤0.01%
1,747
-25,407
-94% -$214K
QID icon
3184
ProShares UltraShort QQQ
QID
$243M
$19K ﹤0.01%
148
-19,505
-99% -$2.42M
QYLD icon
3185
Global X NASDAQ-100 Covered Call ETF
QYLD
$8.29B
$19K ﹤0.01%
1,182
-317
-21% -$5.12K
RRBI icon
3186
Red River Bancshares
RRBI
$680M
$19K ﹤0.01%
385
+38
+11% +$2.07K
SCSC icon
3187
Scansource
SCSC
$1.08B
$19K ﹤0.01%
651
-2,395
-79% -$71.1K
SMRT icon
3188
SmartRent
SMRT
$284M
$19K ﹤0.01%
8,110
-2,207
-21% -$5.46K
TEVA icon
3189
Teva Pharmaceuticals
TEVA
$42.6B
$19K ﹤0.01%
2,128
-1,345
-39% -$11.7K
THS
3190
DELISTED
Treehouse Foods
THS
$19K ﹤0.01%
369
-3,187
-90% -$152K
UONE icon
3191
Urban One Class A
UONE
$23.9M
$19K ﹤0.01%
400
-195
-33% -$10.5K
VRNA
3192
DELISTED
Verona Pharma
VRNA
$19K ﹤0.01%
731
+178
+32% +$2.37K
WHF icon
3193
WhiteHorse Finance
WHF
$152M
$19K ﹤0.01%
+1,511
New +$19.1K
PHLT
3194
DELISTED
Performant Healthcare Inc
PHLT
$19K ﹤0.01%
5,090
-4,356
-46% -$10.2K
BZAI
3195
Blaize Holdings
BZAI
$87.7M
$19K ﹤0.01%
1,847
-106
-5% -$1.07K
ABOS icon
3196
Acumen Pharmaceuticals
ABOS
$188M
$18K ﹤0.01%
3,272
-4,845
-60% -$32.6K
AIR icon
3197
AAR Corp
AIR
$5.86B
$18K ﹤0.01%
403
-5,007
-93% -$218K
AMPH icon
3198
Amphastar Pharmaceuticals
AMPH
$886M
$18K ﹤0.01%
651
-4,492
-87% -$130K
AMPL icon
3199
Amplitude
AMPL
$1.63B
$18K ﹤0.01%
1,504
-3,527
-70% -$49.9K
AMSF icon
3200
AMERISAFE
AMSF
$513M
$18K ﹤0.01%
345
-341
-50% -$18.1K

Similar funds

Tower Research Capital (TRC)'s Q4 2022 Portfolio in Review

As of Q4 2022, Tower Research Capital (TRC) held 6,989 positions worth $2.41B, down 61% from $6.16B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Tower Research Capital (TRC) withdrew a net $4.09B in Q4 2022, closing 686 positions and reducing 3,620 holdings. Its most notable exit was Vanguard Russell 2000 Value ETF, an estimated $4.46M position sold in full.

By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Tower Research Capital (TRC) opened a new position in iShares Semiconductor ETF worth $9.33M.

  • Tower Research Capital (TRC)'s largest Q4 2022 buy was iShares Semiconductor ETF: 80,454 shares worth $9.33M.
  • Tower Research Capital (TRC) added most to iShares Russell 2000 ETF in Q4 2022, an estimated $145M increase.
  • Tower Research Capital (TRC)'s biggest Q4 2022 reduction was Apple, cutting an estimated $322M.
  • Tower Research Capital (TRC) fully exited Vanguard Russell 2000 Value ETF in Q4 2022, selling an estimated $4.46M.
  • Tower Research Capital (TRC)'s ten largest holdings make up 32% of its $2.41B portfolio in Q4 2022.
  • Tower Research Capital (TRC) opened 537 new positions and closed 686 in Q4 2022.
  • Tower Research Capital (TRC)'s portfolio value fell 61% quarter-over-quarter to $2.41B.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2022, filed 10 Feb 2023.